RARE Key Statistics, Chart & Performance
The current stock price of RARE is 24.07 USD. In the past month the price increased by 4.65%. In the past year, price decreased by -44.06%.
RARE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to RARE. When comparing the yearly performance of all stocks, RARE is a bad performer in the overall market: 91.18% of all stocks are doing better.
RARE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RARE. Both the profitability and financial health of RARE have multiple concerns.
RARE Financial Highlights
Over the last trailing twelve months RARE reported a non-GAAP Earnings per Share(EPS) of -5.94. The EPS increased by 8.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.71% | ||
| ROE | -6330.7% | ||
| Debt/Equity | 83.39 |
RARE Forecast & Estimates
27 analysts have analysed RARE and the average price target is 68.9 USD. This implies a price increase of 186.25% is expected in the next year compared to the current price of 24.07.
For the next year, analysts expect an EPS growth of 8.03% and a revenue growth 20.57% for RARE
RARE Ownership
About RARE
Company Profile
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. The company is headquartered in Novato, California and currently employs 1,294 full-time employees. The company went IPO on 2014-01-31. The firm is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
Company Info
ULTRAGENYX PHARMACEUTICAL IN
60 Leveroni Ct
Novato CALIFORNIA 94949 US
CEO: Emil D. Kakkis
Employees: 1294
Phone: 14154838800
ULTRAGENYX PHARMACEUTICAL IN / RARE FAQ
What does ULTRAGENYX PHARMACEUTICAL IN do?
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. The company is headquartered in Novato, California and currently employs 1,294 full-time employees. The company went IPO on 2014-01-31. The firm is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
Can you provide the latest stock price for ULTRAGENYX PHARMACEUTICAL IN?
The current stock price of RARE is 24.07 USD. The price decreased by -0.82% in the last trading session.
Does ULTRAGENYX PHARMACEUTICAL IN pay dividends?
RARE does not pay a dividend.
How is the ChartMill rating for ULTRAGENYX PHARMACEUTICAL IN?
RARE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for ULTRAGENYX PHARMACEUTICAL IN?
ULTRAGENYX PHARMACEUTICAL IN (RARE) operates in the Health Care sector and the Biotechnology industry.
Can you provide the number of employees for ULTRAGENYX PHARMACEUTICAL IN?
ULTRAGENYX PHARMACEUTICAL IN (RARE) currently has 1294 employees.
Can you provide the upcoming earnings date for ULTRAGENYX PHARMACEUTICAL IN?
ULTRAGENYX PHARMACEUTICAL IN (RARE) will report earnings on 2026-02-12, after the market close.